Stealth BioTherapeutics Corp. ADS
MITO
MITO was delisted on the 15th of November, 2022.
5 hedge funds and large institutions have $752K invested in Stealth BioTherapeutics Corp. ADS in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
29% less funds holding
Funds holding: 7 → 5 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
72% less capital invested
Capital invested by funds: $2.69M → $752K (-$1.93M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBHC
Brown Brothers Harriman & Co
New York
|
+$1.34M |
| 2 |
Morgan Stanley
New York
|
+$76.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$2.38M |
| 2 |
Millennium Management
New York
|
-$158K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$98K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$46 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BBHC
1
Brown Brothers Harriman & Co
New York
| $570K | +$1.34M | +174,999 | New |
|
|
IC
2
Ikarian Capital
Dallas,
Texas
| $123K | +$288K | +37,597 | New |
|
|
3
Morgan Stanley
New York
| $36K | +$76.7K | +10,000 | +1,000% |
|
|
4
UBS Group
Zurich,
Switzerland
| $23K | +$2.19K | +286 | +4% |
|
|
KCM
5
Kingdon Capital Management
New York
| – | -$2.38M | -398,169 | Closed |
|
|
6
Millennium Management
New York
| – | -$158K | -26,437 | Closed |
|
|
7
Bank of America
Charlotte,
North Carolina
| – | -$98K | -16,452 | Closed |
|
|
8
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$2K | -348 | Closed |
|
|
9
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$46 | -6 | -21% |
|
MITO Hedge Fund Activity: Q4 2019 in Review
5 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Stealth BioTherapeutics Corp. ADS (MITO) for Q4 2019, worth a combined $752K — down 72% from $2.69M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MITO and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Brown Brothers Harriman & Co, opening a new position worth an estimated $1.34M. The largest seller was Kingdon Capital Management, exiting entirely with an estimated $2.38M sold.
- 5 institutional investors held Stealth BioTherapeutics Corp. ADS (MITO) as of Q4 2019, down from 7 in Q3 2019.
- Funds reported $752K of Stealth BioTherapeutics Corp. ADS stock for Q4 2019, down 72% quarter-over-quarter.
- 2 funds opened new Stealth BioTherapeutics Corp. ADS positions in Q4 2019 and 4 closed out, a net change of -2 holders.
- The largest Stealth BioTherapeutics Corp. ADS buyer in Q4 2019 was Brown Brothers Harriman & Co, an estimated $1.34M added.
- The largest Stealth BioTherapeutics Corp. ADS seller in Q4 2019 was Kingdon Capital Management, an estimated $2.38M sold.
Based on aggregated 13F filings for Q4 2019.